Myeloma
Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Cecilia BrownMyeloma | December 2, 2022
Iberdomide plus dexamethasone showed encouraging efficacy and safety in triple-class-exposed R/R myeloma anti-BCMA therapy.
Read More
Cecilia BrownMyeloma | December 2, 2022
A GPRC5D-targeted autologous chimeric antigen receptor (CAR) T-cell therapy had “promising” preliminary efficacy.
Leah SherwoodMyeloma | December 1, 2022
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse. 
Cecilia BrownMyeloma | November 15, 2022
No dose-limiting toxicities occurred in patients with relapsed/refractory multiple myeloma who were treated with agenT-797...
Cecilia BrownMyeloma | November 9, 2022
Findings support daratumumab plus lenalidomide and dexamethasone treatment for at least 18 months in MM...
Cecilia BrownMyeloma | November 9, 2022
Ciltacabtagene autoleucel led to responses in 61.5% of patients with multiple myeloma...
Leah SherwoodMyeloma | November 8, 2022
The phase III DREAMM-3 trial did not meet its primary endpoint...
Cecilia BrownTransplantation & Cellular Therapy | November 4, 2022
A GPRC5D-targeted CAR T-cell therapy led to a 71% response rate in patients with heavily pretreated multiple myeloma...
Leah SherwoodMyeloma | October 25, 2022
The FDA has granted accelerated approval for the use of teclistamab in adults with relapsed or refractory multiple myeloma.
Leah SherwoodMyeloma | October 25, 2022
Health-related quality of life improved in patients with R/R MM following treatment with the CAR T-cell treatment...
Kerri FitzgeraldMyeloma | October 14, 2022
A single infusion of ciltacabtagene autoleucel led to impressive overall response rates...
Kerri FitzgeraldMyeloma | October 14, 2022
A new study suggests the current reference intervals for serum free light chain concentrations...
Kerri FitzgeraldMyeloma | October 14, 2022
Talquetamab demonstrated “highly promising efficacy” in heavily pretreated patients with...
Cecilia BrownMyeloma | October 13, 2022
The phase I/II MajesTEC-1 study demonstrated that teclistamab produced a high rate of deep...
Cecilia BrownMyeloma | October 13, 2022
We are entering the great era of immunotherapy in multiple myeloma, as we’ve had significant...
Cecilia BrownMyeloma | October 13, 2022
The European Commission (EC) has granted marketing authorization for melphalan flufenamide...
Cecilia BrownMyeloma | October 13, 2022
The European Commission granted Conditional Marketing Authorization for teclistamab as a...
Leah SherwoodMyeloma | October 10, 2022
The committee overwhelmingly voted that melphalan flufenamide has not demonstrated benefit...
Leah SherwoodMyeloma | September 30, 2022
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, provides an update...
Kerri FitzgeraldMyeloma | September 13, 2022
Antibiotic prophylaxis should be considered an option for patients with newly diagnosed multiple myeloma...
Advertisement
Editorial Board

Advertisement